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Background
Targeted toxins have the potential to overcome intrinsic or
acquired resistance of cancer cells to conventional cytotoxic
agents. We hypothesized that EGFuPA-toxin, a bispecific
ligand-targeted toxin consisting of a deimmunized Pseudo-
monas exotoxin conjugated to epidermal growth factor
(EGF) and urokinase (uPA), would efficiently target and kill
cells derived from canine hemangiosarcoma (HSA), a highly
chemotherapy resistant tumor, as well as cultured heman-
giospheres, used as a surrogate for cancer stem cells (CSC).
Materials and methods
We evaluated EGFuPA-toxin activity in four HSA cell
lines (Emma, Frog, DD-1, and SB), using a feline mam-
mary carcinoma cell line (K12) and a human T-cell leu-
kemia line (Jurkat) as controls. Hemangiospheres were
grown under serum-free low adherence conditions to
enrich cancer stem cells. Cytotoxicity was determined
using the CellTiter96 AQueous viability assay. Specificity
for cells expressing cognate receptors was confirmed
using neutralizing antibodies and competitive binding
assays. Relative receptor expression in target cell lines
was verified using flow cytometry.
Results
EGFuPA-toxin showed cytotoxicity in each of the HSA
cell lines tested at concentrations ≤100 nM that was
dependent on specific ligand-receptor interactions.
Monospecific targeted toxins also killed HSA cells; in
this case, a “threshold” level of EGFR expression
appeared to be required to make cells sensitive to
monospecific EGF-toxin, but not to monospecific uPA-
toxin. The IC50 of CSCs was higher by approximately
two orders of magnitude compared to non-CSCs, but
these cells were still sensitive to EGFuPA-toxin at nano-
molar (i.e., pharmacologically relevant) concentrations.
Conclusions
Our results support the use of these toxins to treat chemore-
sistant tumors such as sarcomas, including those that con-
form to the cancer stem cell model. Our results also support
the use of companion animals with cancer for further trans-
lational development of these cytotoxic molecules.
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